Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Trial Profile

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Sugammadex (Primary)
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2015 Primary endpoint has been met. (determine a profound neuromuscular blockade reversal on ideal body weight), as published in the Anaesthesia
    • 19 Dec 2015 Results published in the Anaesthesia
    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top